Positions

Overview

  • Janusz H.S. Kabarowski received his B.Sc. degree in Biochemistry from University College London, UK. He was awarded a Ph.D. degree from the Leukaemia Research Fund centre at The Institute of Cancer Research (Chester Beatty Laboratories) in London in 1997. Dr. Kabarowski subsequently conducted postdoctoral research in the laboratory of Owen Witte at UCLA. Dr. Kabarowski joined the Department of Microbiology at UAB as an Assistant Professor in 2003 and has a secondary faculty appointment in the Department of Pathology, Division of Molecular and Cellular Pathology.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 G2A Protects Mice against Sepsis by Modulating Kupffer Cell Activation: Cooperativity with Adenosine Receptor 2b.Journal of Immunology.  202:527-538. 2019
    2018 Genetic deletion of 12/15 lipoxygenase promotes effective resolution of inflammation following myocardial infarction.Journal of Molecular and Cellular Cardiology.  118:70-80. 2018
    2016 Training in metabolomics research. II. Processing and statistical analysis of metabolomics data, metabolite identification, pathway analysis, applications of metabolomics and its future.Journal of Mass Spectrometry.  51:535-548. 2016
    2016 Training in metabolomics research. II. Processing and statistical analysis of metabolomics data, metabolite identification, pathway analysis, applications of metabolomics and its future.Journal of Mass Spectrometry.  51:ii-iii. 2016
    2016 Training in metabolomics research. I. Designing the experiment, collecting and extracting samples and generating metabolomics data.Journal of Mass Spectrometry.  51:461-475. 2016
    2016 Effect of n-3 and n-6 Polyunsaturated Fatty Acids on Microsomal P450 Steroidogenic Enzyme Activities and In Vitro Cortisol Production in Adrenal Tissue From Yorkshire Boars.Endocrinology.  157:1512-1521. 2016
    2016 Early lipid changes in acute kidney injury using SWATH lipidomics coupled with MALDI tissue imaging.AJP - Renal Physiology.  310:F1136-F1147. 2016
    2015 Cholesterol-Independent Suppression of Lymphocyte Activation, Autoimmunity, and Glomerulonephritis by Apolipoprotein A-I in Normocholesterolemic Lupus-Prone Mice.Journal of Immunology.  195:4685-4698. 2015
    2015 Interferon-induced mechanosensing defects impede apoptotic cell clearance in lupus.Journal of Clinical Investigation.  125:2877-2890. 2015
    2015 Obesity superimposed on aging magnifies inflammation and delays the resolving response after myocardial infarction.AJP - Heart and Circulatory Physiology.  308:H269-H280. 2015
    2015 Calreticulin Regulates Neointima Formation and Collagen Deposition following Carotid Artery Ligation.Journal of Vascular Research.  52:306-320. 2015
    2015 Early changes in vascular reactivity in response to 56Fe irradiation in ApoE-/- miceActa Astronautica.  108:40-45. 2015
    2014 Increased sensitivity of Apolipoprotein E knockout mice to swainsonine dependent immunomodulation.Immunobiology.  219:497-502. 2014
    2013 CD36, but not G2A, modulates efferocytosis, inflammation, and fibrosis following bleomycin-induced lung injury.Journal of Lipid Research.  54:1114-1123. 2013
    2011 Iron-ion radiation accelerates atherosclerosis in apolipoprotein E-deficient mice.Radiation Research.  175:766-773. 2011
    2011 Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice.Arthritis and Rheumatism.  63:201-211. 2011
    2009 G2A and LPC: regulatory functions in immunity.Prostaglandins and Other Lipid Mediators.  89:73-81. 2009
    2009 ApoE-dependent modulation of HDL and atherosclerosis by G2A in LDL receptor-deficient mice independent of bone marrow-derived cells.Arteriosclerosis, Thrombosis, and Vascular Biology.  29:539-547. 2009
    2009 Deletion of the G2A receptor fails to attenuate experimental autoimmune encephalomyelitis.Journal of Neuroimmunology.  207:18-23. 2009
    2006 Loss of the lysophosphatidylcholine effector, G2A, ameliorates aortic atherosclerosis in low-density lipoprotein receptor knockout mice.Arteriosclerosis, Thrombosis, and Vascular Biology.  26:2703-2709. 2006
    2005 Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4.Journal of Biological Chemistry.  280:43280. 2005
    2005 Loss of G2A promotes macrophage accumulation in atherosclerotic lesions of low density lipoprotein receptor-deficient mice.Journal of Lipid Research.  46:1405-1415. 2005
    2005 Retraction.Science.  307:206. 2005
    2002 Lysophosphatidylcholine as a ligand for immunoregulation.Biochemical Pharmacology.  64:161-167. 2002
    2002 Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene.Cancer Cell.  1:381-391. 2002
    2001 Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4.Journal of Biological Chemistry.  276:41325-41335. 2001
    2001 Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A.Science.  293:702-705. 2001
    2001 Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome.Immunity.  14:561-571. 2001
    2000 Direct genetic demonstration of G alpha 13 coupling to the orphan G protein-coupled receptor G2A leading to RhoA-dependent actin rearrangement.Proceedings of the National Academy of Sciences.  97:12109-12114. 2000
    2000 Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia.STEM CELLS.  18:399-408. 2000
    1999 Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene.Oncogene.  18:365-375. 1999
    1998 Haemopoietic transformation by the TEL/ABL oncogene.British Journal of Haematology.  102:475-485. 1998
    1997 Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies.Proceedings of the National Academy of Sciences.  94:10255-10260. 1997
    1996 ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block.Oncogene.  13:2225-2234. 1996
    1994 A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells.EMBO Journal.  13:5887-5895. 1994
    1992 A simplified method of detection of clonal rearrangements of the T-cell receptor-gamma chain gene.Diagnostic Molecular Pathology.  1:173-179. 1992
    1992 Ph1 positive chronic granulocytic leukaemia developing in a patient with primary proliferative polycythaemia: Case report and literature reviewLeukemia & Lymphoma.  6:423-425. 1992
    1991 The rapid detection of clonal T-cell proliferations in patients with lymphoid disorders.American Journal of Pathology.  138:821-828. 1991

    Research Overview

  • Lipids and lipoprotein metabolism in chronic inflammatory disease - Dr. Kabarowski’s research program is focused on the study of lipids and lipoprotein metabolism in chronic inflammatory disease (notably atherosclerosis and autoimmune disease). Early work characterized the role of the G2A lipid receptor in atherosclerosis and lipoprotein metabolism, showing that pro-atherogenic effects of this receptor may be mediated through its modulatory influence on hepatic High-Density Lipoprotein (HDL) biogenesis. More recently, Dr. Kabarowski’s group described autoimmune-mediated effects on HDL metabolism in normolipidemic mouse models of Systemic Lupus Erythematosus (SLE) and currently a major effort of his laboratory is directed toward developing therapeutic approaches by which anti-inflammatory and immunosuppressive properties of HDL may be harnessed to improve major Lupus phenotypes and combat premature atherosclerosis, a major cause of morbidity and mortality in this and other rheumatic autoimmune diseases. Emphasis is placed on determining the mechanisms by which protective anti-inflammatory properties of HDL are subverted by chronic inflammation, understanding how this influences immunoregulatory processes involved in SLE and atherosclerosis, and establishing the therapeutic efficacy of HDL-targeted approaches such as HDL mimetic peptides in SLE and other autoimmune diseases.

    Keywords - Atherosclerosis, Autoimmunity, HDL, Lipids, Inflammation
  • Investigator On

  • UAB-UCSD O'Brien Center For Acute Kidney Injury Research  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB-UCSD O'Brien Core Center for Acute Kidney Injury Research - Core C  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • Border-Associated Macrophages in an Alpha-Synuclein Overabundance Model of Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2021
  • HDL and Cellular Repair Mechanisms  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2016 - 2020
  • Cellular Lipids and Leukocyte Function  awarded by National Institute of General Medical Sciences/NIH/DHHS 2015 - 2019
  • Ethnic Differences in Responses to Painful Stimuli  awarded by University of Florida 2014 - 2018
  • Radiation-Induced Early Changes in Gene and Protein Expression, Lipid Oxidative States, and Vascular Function Related to Atherosclerosis  awarded by NASA - National Aeronautics & Space Administration 2014 - 2016
  • Mechanisms, Early Events, and Dose Dependence of Radiation-Induced Atherosclerosis  awarded by NASA - National Aeronautics & Space Administration 2011 - 2015
  • Training Program in Cardiovascular Pathophysiology  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2014 - 2015
  • Rheumatic Diseases Core Center  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2008 - 2012
  • Full Name

  • Janusz Kabarowski